LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Quidel Corp

Uždarymo kaina

29.57 -8.34

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.46

Max

32.37

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

6,600

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+35.89% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

215M

2B

Ankstesnė atidarymo kaina

37.91

Ankstesnė uždarymo kaina

29.57

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-21 23:25; UTC

Karštos akcijos

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

2025-05-21 21:57; UTC

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

2025-05-21 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Operations in Uruguay

2025-05-21 21:01; UTC

Pagrindinės rinkos jėgos

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

2025-05-21 23:49; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

2025-05-21 23:37; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-05-21 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

2025-05-21 23:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

2025-05-21 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

2025-05-21 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

2025-05-21 23:28; UTC

Uždarbis

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

2025-05-21 23:27; UTC

Uždarbis

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

2025-05-21 23:23; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

2025-05-21 23:22; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

2025-05-21 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

2025-05-21 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

2025-05-21 23:04; UTC

Svarbiausios naujienos

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

2025-05-21 21:42; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

2025-05-21 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Ops in Uruguay

2025-05-21 21:07; UTC

Svarbiausios naujienos

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

2025-05-21 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

2025-05-21 20:59; UTC

Svarbiausios naujienos

Walmart to Cut 1,500 Jobs -- WSJ

2025-05-21 20:52; UTC

Uždarbis

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

35.89% į viršų

12 mėnesių prognozė

Vidutinis 44 USD  35.89%

Aukščiausias 60 USD

Žemiausias 27 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

3

Pirkti

2

Laikyti

1

Parduoti

Finansinės naujienos

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.